Pharma is often presented as a single AI opportunity called drug discovery. The operating reality is much broader. A life-sciences company has experimental data, clinical protocols, investigator conversations, safety narratives, manufacturing records, regulatory commitments, scientific literature, and country-specific commercial rules. Each source has a different owner, vocabulary, risk, and evidence standard.
That makes pharma a strong market for a portfolio of specialized models. A scientific foundation model may help rank a target. A document model may structure a protocol. A speech model may capture an investigator call. A small language model may classify an adverse-event report. A retrieval system may assemble the evidence behind a regulatory answer. The value comes from connecting these systems to an accountable workflow.
The adoption signal is already visible
The US Food and Drug Administration reports experience with more than 500 drug and biological product submissions containing AI components since 2016. The agency says AI applications span nonclinical, clinical, postmarketing, and manufacturing phases.
This is not only experimental science. Sanofi's 2025 Form 20-F says its Plai platform was available to more than 22,000 employees. Its SimpLY manufacturing application had analyzed more than 13,000 batch runs and was associated with estimated annual savings of about EUR 10 million. Sanofi also reports that AI-supported research generated seven novel targets during the year.
Moderna's enterprise deployment provides a different adoption pattern. The company reported more than 80% employee adoption of its internal assistant, 750 custom GPTs created within two months, and an average of 120 conversations per active user each week. Forty percent of weekly active users had built a GPT themselves. These are company and technology-provider figures, but they show that model use can move beyond a central data-science team.
Where the models fit
Where the models fit
Discovery and preclinical research
Scientific models can support target identification, protein and molecule representation, literature triage, assay design, structure prediction, toxicity forecasting, and...
Clinical development
Models can identify eligible trial sites, forecast enrollment, extract inclusion and exclusion criteria, compare protocols, detect operational risk, draft patient-facing...
Regulatory intelligence and submission operations
Regulatory teams can use enterprise RAG to compare authority guidance, health-agency questions, prior responses, commitments, labeling decisions, and the evidence in a...
Pharmacovigilance and medical information
Specialized classifiers can identify reportable events across email, call transcripts, literature, patient-support programs, and product complaints.
Manufacturing and quality
Time-series models can detect process drift, predict deviations, forecast yield, and prioritize maintenance.
Supply, medical, and commercial operations
Models can forecast demand, identify cold-chain exceptions, optimize inventory, support field medical teams, translate approved content, and help contact centers answer product...
Discovery and preclinical research
Scientific models can support target identification, protein and molecule representation, literature triage, assay design, structure prediction, toxicity forecasting, and experiment prioritization. A language model can summarize evidence, but experimental and statistical models should produce the scientific score.
The useful output is not a fluent hypothesis alone. It is a traceable claim connected to papers, assay results, data provenance, uncertainty, and the next experiment. Measure enrichment over baseline, prospective hit rate, failed-experiment reduction, scientist review time, and time between design and test.
Clinical development
Models can identify eligible trial sites, forecast enrollment, extract inclusion and exclusion criteria, compare protocols, detect operational risk, draft patient-facing language, and classify site questions. Speech and document intelligence can structure investigator calls, monitoring notes, and patient-reported information.
The critical controls are protocol version, country, trial phase, protected-health-information access, and human approval. A model that retrieves a correct criterion from the wrong amendment is still wrong.
Regulatory intelligence and submission operations
Regulatory teams can use enterprise RAG to compare authority guidance, health-agency questions, prior responses, commitments, labeling decisions, and the evidence in a submission. Document models can identify obligations, dates, products, indications, jurisdictions, and cross-references.
The FDA and European Medicines Agency's joint principles emphasize context of use, risk-based development, data governance, standards, human oversight, and lifecycle monitoring. The implication is practical: a model used to locate a precedent has a different validation burden from a model that contributes to a benefit-risk conclusion.
Pharmacovigilance and medical information
Specialized classifiers can identify reportable events across email, call transcripts, literature, patient-support programs, and product complaints. Extraction models can capture patient, reporter, product, dose, event, seriousness, outcome, and time. RAG can help medical-information teams draft an answer from approved response documents and current labeling.
Recall matters more than polished prose at intake. The system must preserve the original evidence, surface uncertainty, support duplicate detection, and route cases within required timelines.
Manufacturing and quality
Time-series models can detect process drift, predict deviations, forecast yield, and prioritize maintenance. Document and language models can compare batch records, standard operating procedures, deviations, corrective and preventive actions, and change controls. Sanofi says its generative-AI quality-report workflow can reduce time and effort by as much as 80%, a company-reported result that should be validated locally.
Supply, medical, and commercial operations
Models can forecast demand, identify cold-chain exceptions, optimize inventory, support field medical teams, translate approved content, and help contact centers answer product questions. Commercial systems require label, indication, geography, audience, consent, and promotional controls.
One model is not the architecture
| Layer | Suitable model | Core control | Useful metric |
|---|---|---|---|
| Scientific prediction | graph, sequence, multimodal model | data provenance and prospective validation | hit rate, calibration |
| Clinical documents | extraction model and SLM | protocol version and PHI access | field accuracy, reviewer time |
| Scientific knowledge | enterprise RAG | source, date, jurisdiction, citation | retrieval recall, citation precision |
| Safety intake | ASR, classifier, entity extractor | high recall and human case review | missed-case rate, processing time |
| Manufacturing | time-series and anomaly model | validated data and change control | deviation lead time, yield |
| Medical voice | domain ASR and constrained agent | approved response and escalation | entity accuracy, correct resolution |
| Workflow action | rules and APIs | permission, approval, audit | unauthorized action rate |
The language model should rarely own the final regulated action. It can interpret, retrieve, compare, and draft. A deterministic workflow should validate required fields, apply policy, request approval, and write to the system of record.
The private knowledge advantage
A generic model knows public biology and language. It does not know the company's negative experiments, latest protocol amendment, quality history, approved claims, response letters, or local operating procedures. That context is where an enterprise builds advantage.
The knowledge layer should preserve document identity, effective dates, authority, product, geography, and access. Retrieval evaluation should test obsolete-document traps, contradictory sources, missing evidence, and questions that must be refused.
A production scorecard
Do not begin with generic productivity. Pick an accountable workflow and establish:
- Current cycle time, backlog, rework, and error cost.
- Model quality at the field, evidence, and decision-support levels.
- Percentage of outputs accepted unchanged, corrected, escalated, or rejected.
- Missed safety signals, incorrect citations, and permission failures.
- Time from new evidence or guidance to updated model behavior.
- Cost per completed, quality-controlled unit of work.
A useful pilot might be protocol feasibility, medical-information drafting, safety intake, deviation triage, or batch-record review. Run it retrospectively, then in shadow mode, then as human assist. Grant bounded actions only after the error distribution is understood.
The conclusion
The pharma AI opportunity is a connected model stack, not a single scientific model. Specialized systems can shorten work across research, development, safety, quality, and operations while preserving the evidence chain each function needs.
The durable asset is not access to a frontier model. It is the company's validated data, scientific and regulatory knowledge, expert corrections, and evaluation system.
Research note
Research is current through September 5, 2026. Regulatory and company metrics are attributed to their publishers. Vendor-supported case studies are directional evidence, not guaranteed outcomes. Any regulated use requires a context-specific quality, privacy, validation, and human-oversight assessment.
Continue the research
- Regulatory RAG for pharma submissions
- AI for pharmacovigilance and medical information
- Why enterprises should use small language models
- How enterprise model routing balances quality and cost
- The enterprise AI model stack for healthcare
Building a Production-Ready System
Conscious Engines builds AI for pharma and life sciences across scientific, clinical, regulatory, safety, manufacturing, and medical-information workflows. We combine specialist prediction, speech, document, SLM, and RAG components under context-specific evaluation, validation, and human review.